About BioQ Pharma
BioQ Pharma is a Healthcare company based in United States founded in 2003. Readytouse infusible pharmaceuticals for post-surgical pain and sedation. BioQ Pharma has raised $84.58 million across 11 funding rounds from investors including IIG PLC, Madryn Asset Management and Military Health. The company has 15 employees. BioQ Pharma offers products and services including invenious™ Platform, Ropivacaine ReadyfusOR®, and invenious™/propofol. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is BioQ Pharma, Inc. Its competitors include Biogen, Insulet and Neurocrine; 3 of its 3 listed competitors have raised funding.
Company details
BioQ Pharmanbsp;(formerly known as BioQuiddity)nbsp;is a late-stage specialty pharmaceutical company focused onnbsp;the portfolio of large volume ready-to-use infusible pharmaceuticals using its infusion platform. The platform includes a unit dose of the drug, delivery system and administration line in one self-contained and ready-to-use presentation.nbsp;Its lead products include Ropivacaine (approved in EU) and Propofol for post-surgical pain and anesthesia. Additionally, it has four products in the development stage for sedation, antibiotics and oncology.
- Headquarters United States
- Employees 15
- SectorsHealthcare
- Website bioqpharma.com
- Social X
- Legal Name Bioq Pharma, Inc.
- Total Equity Funding$84.58M (USD)
in 11 rounds
- Latest Funding Round$4.64M (USD), Series D
Jan 2020
- InvestorsIIG PLC
& 2 more
- Employee Count15
Products & Services of BioQ Pharma
BioQ Pharma offers a comprehensive portfolio of products and services, including invenious™ Platform, Ropivacaine ReadyfusOR®, and invenious™/propofol.
Transforms infusible medicines into ready-to-use systems for safer administration.
Provides tailored delivery for the Ropivacaine drug.
Offers connect-and-go solution for propofol administration.
Funding Insights of BioQ Pharma
BioQ Pharma has successfully raised a total of $84.58M across 11 strategic funding rounds. The most recent funding activity was a Series D round of $4.64 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84.58M
- Total Rounds 11
- Last Round Series D — $4.64M
- First Round $1.09M
(Feb 2004)
- Investors Count 3
Latest 10 of 11 funding rounds of BioQ Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $4.64M | Series D | – | IIG | – |
| Nov 2018 | $36.41M | Series D | – | Madryn Asset Management | – |
| Oct 2016 | $15.04M | Series C | – | – | – |
| Nov 2014 | $13.74M | Series B | – | – | – |
| Apr 2013 | $8.07M | Series B | – | – | – |
| Jan 2010 | $7.03M | Grant | – | – | |
| Jul 2007 | $5.32M | Series A | – | – | – |
| Dec 2006 | $7.03M | Grant | – | – | |
| Dec 2006 | $7.03M | Grant | – | – | |
| Dec 2004 | $279,500 | Seed | – | – | – |
3 investors in total: 3 institutional.
Investors in BioQ Pharma
BioQ Pharma has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include IIG PLC, Madryn Asset Management and Military Health.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are directed by IIG toward life sciences startups. | 2020 | iigplc.com | London, United Kingdom | |
Diversified asset management is provided by the firm. | 2017 | madrynlp.com | New York, United States | |
Administers health care and support for military personnel and operations. | health.mil | Falls Church, United States |
Investor details for BioQ Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioQ Pharma
17 people are tracked at BioQ Pharma (6 in leadership, 7 in board & advisors, 4 in team); the tracked headcount is 15.
| Name | Role | Group |
|---|---|---|
Richard Watts | VP of Intellectual Property | Leadership |
Ralph McNall | VP of Engineering | Leadership |
Josh Kriesel | CEO | Leadership |
Christopher Vega | VP, Controller | Leadership |
Ronald Pauli | CFO | Leadership |
Walter Cleymans | Chief Commercial Officer | Leadership |
Richard Nesbit | Board Member | Board & advisors |
N. William Jasper Jr. | Board Member | Board & advisors |
David J. Teece | Strategic Advisor | Board & advisors |
Marijn Dekkers | Strategic Advisor | Board & advisors |
Christopher Portman | Board Member | Board & advisors |
Daniel Tassé | Board Member | Board & advisors |
Llew Keltner | Board Member | Board & advisors |
Neil Pearson | Product Design Engineer | Team |
Dominique Vandenberghe | QA Support/qp | Team |
Alexander Saguna | Product Engineer | Team |
Thida Aung | Assistant Controller | Team |
Complete people profiles for BioQ Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioQ Pharma
3 dated milestones of BioQ Pharma across 17 years, from founding to its latest funding, stage changes and deals.
- Founded BioQ Pharma is founded.
- Funding First funding round of $1.1M.
- Funding Latest funding round, Series D, of $4.6M.
Competitors of BioQ Pharma
BioQ Pharma has 3 listed competitors in our database, 3 of them funded. They include Biogen, Insulet and Neurocrine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| insulet.com | 2000 | Boston, United States | $120.4M | 2,600 | Wearable insulin infusion systems are developed for diabetes patients. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders |
Detailed competitors of BioQ Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as BioQ Pharma (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioq Pharma
Complete news archive for BioQ Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioQ Pharma
BioQ Pharma was founded in 2003 and raised its 1st funding round 1 year after it was founded.
BioQ Pharma is headquartered in United States.
BioQ Pharma is a funded company, having raised a total of $84.58M across 11 funding rounds to date. The company's 1st funding round was a Seed of $279.5K, raised on Feb 2004.
BioQ Pharma has 15 employees.
BioQ Pharmanbsp;(formerly known as BioQuiddity)nbsp;is a late-stage specialty pharmaceutical company focused onnbsp;the portfolio of large volume ready-to-use infusible pharmaceuticals using its infusion platform. The platform includes a unit dose of the drug, delivery system and administration line in one self-contained and ready-to-use presentation.nbsp;Its lead products include Ropivacaine (approved in EU) and Propofol for post-surgical pain and anesthesia. Additionally, it has four products in the development stage for sedation, antibiotics and oncology.
BioQ Pharma's top competitors include Insulet, Neurocrine and Biogen.
BioQ Pharma offers invenious™ Platform, Ropivacaine ReadyfusOR®, and invenious™/propofol.
BioQ Pharma has 3 investors. Key investors include IIG PLC, Madryn Asset Management, and Military Health.
BioQ Pharma operates through Bioq Pharma, Inc..